Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Oral Vinorelbine and Cisplatin as Induction Chemotherapy and Concomitant Chemo-Radiotherapy in Stage III Non-small Cell Lung Cancer Final Results of an International Phase II Trial

Oral Vinorelbine and Cisplatin as Induction Chemotherapy and Concomitant Chemo-Radiotherapy in... ORIGINAL ARTICLE Oral Vinorelbine and Cisplatin as Induction Chemotherapy and Concomitant Chemo-Radiotherapy in Stage III Non-small Cell Lung Cancer Final Results of an International Phase II Trial Maciej Krzakowski, MD, Mariano Provencio, MD, Beata Utracka-Hutka, MD,† Eugenio Villa, MD, Manuel Codes, MD, Abraham Kuten, MD, Michael Henke, MD, Massimo Lopez, MD, David Bell, MD, Giampaolo Biti, MD, Ofer Merimsky, MD, Aulo Beorchia, MD, Marcello Riggi, MD, Noe¨l-Raphae¨l Caux, MSc, Jean-Christophe Pouget, MSc, Bernard Dubray, MD, and Philippe David, MD 86%/93% and 97%/98% at induction and in combination with Introduction: Cisplatin in combination with vinorelbine has re- radiotherapy, respectively. Forty-one patients (76%) increased oral ported an optimal activity/tolerance ratio when used in combination vinorelbine from 60 to 80 mg/m day during induction (reasons for with radiotherapy in locally advanced unresectable non-small cell nonescalation: hematological 7 patients, nonhematological 2 pa- lung cancer. The currently available oral formulation of vinorelbine tients, error 4 patients). After two cycles of chemotherapy induction, should be easier to use assuming a similar activity profile. An the OR intent-to-treat in the 54 patients was 37%. Toxicities during international phase II trial with vinorelbine oral and cisplatin as induction were as follows: Neutropenia G3–4 (28%), Febrile Neu- induction http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Oral Vinorelbine and Cisplatin as Induction Chemotherapy and Concomitant Chemo-Radiotherapy in Stage III Non-small Cell Lung Cancer Final Results of an International Phase II Trial

Journal of Thoracic Oncology , Volume 3 (9) – Sep 1, 2008

Loading next page...
 
/lp/wolters-kluwer-health/oral-vinorelbine-and-cisplatin-as-induction-chemotherapy-and-0Awr9zWq7a

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864
DOI
10.1097/JTO.0b013e31818396cb
pmid
18758302
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Oral Vinorelbine and Cisplatin as Induction Chemotherapy and Concomitant Chemo-Radiotherapy in Stage III Non-small Cell Lung Cancer Final Results of an International Phase II Trial Maciej Krzakowski, MD, Mariano Provencio, MD, Beata Utracka-Hutka, MD,† Eugenio Villa, MD, Manuel Codes, MD, Abraham Kuten, MD, Michael Henke, MD, Massimo Lopez, MD, David Bell, MD, Giampaolo Biti, MD, Ofer Merimsky, MD, Aulo Beorchia, MD, Marcello Riggi, MD, Noe¨l-Raphae¨l Caux, MSc, Jean-Christophe Pouget, MSc, Bernard Dubray, MD, and Philippe David, MD 86%/93% and 97%/98% at induction and in combination with Introduction: Cisplatin in combination with vinorelbine has re- radiotherapy, respectively. Forty-one patients (76%) increased oral ported an optimal activity/tolerance ratio when used in combination vinorelbine from 60 to 80 mg/m day during induction (reasons for with radiotherapy in locally advanced unresectable non-small cell nonescalation: hematological 7 patients, nonhematological 2 pa- lung cancer. The currently available oral formulation of vinorelbine tients, error 4 patients). After two cycles of chemotherapy induction, should be easier to use assuming a similar activity profile. An the OR intent-to-treat in the 54 patients was 37%. Toxicities during international phase II trial with vinorelbine oral and cisplatin as induction were as follows: Neutropenia G3–4 (28%), Febrile Neu- induction

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Sep 1, 2008

References